Acrivon Therapeutics (ACRV) Income from Continuing Operations (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Income from Continuing Operations of 22511000.0 for Q1 2026, up 12.1% year-over-year from 20081044.62 in Q1 2025, and down 6.35% quarter-over-quarter from 21167000.0 in Q4 2025.
Acrivon Therapeutics (ACRV) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Income from Continuing Operations for 6 consecutive years, with 22511000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 12.1% year-over-year to 22511000.0; the TTM figure through Mar 2026 stood at 86915000.0 (up 21.84% YoY), while the FY2025 annual figure was 85414000.0, up 41.44% from the prior year.
- Income from Continuing Operations fell to 22511000.0 in Q1 2026 per ACRV's latest filing, from 21167000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 5925000.0 in Q2 2022 and bottomed at 35113000.0 in Q1 2023.
- Historically, Income from Continuing Operations has averaged 22605705.88 across 5 years, with a median of 23053000.0 in 2025.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 496.48% — and 2025, when it surged 40.09%.
- Acrivon Therapeutics' Income from Continuing Operations stood at 10245000.0 in 2022, then slumped by 108.42% to 21353000.0 in 2023, then fell by 19.21% to 25454000.0 in 2024, then advanced by 16.84% to 21167000.0 in 2025, then declined by 6.35% to 22511000.0 in 2026.
- Business Quant data shows ACRV's Income from Continuing Operations at 22511000.0 in Q1 2026, 21167000.0 in Q4 2025, and 20184000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Acrivon Therapeutics | 92.89 Mn | 92.89 Mn | - | -17.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20.93 Mn |
| Mar 31, 2026 | -22.51 Mn |
| Dec 31, 2025 | -21.17 Mn |
| Sep 30, 2025 | -20.18 Mn |
| Jun 30, 2025 | -23.05 Mn |
| Mar 31, 2025 | -25.61 Mn |
| Dec 31, 2024 | -25.45 Mn |
| Sep 30, 2024 | -33.69 Mn |
| Jun 30, 2024 | -26.44 Mn |
| Mar 31, 2024 | -27.10 Mn |
| Dec 31, 2023 | -21.35 Mn |
| Sep 30, 2023 | -28.28 Mn |
| Jun 30, 2023 | -35.02 Mn |
| Mar 31, 2023 | -35.11 Mn |
| Dec 31, 2022 | -10.25 Mn |
| Sep 30, 2022 | -15.93 Mn |
| Jun 30, 2022 | -5.93 Mn |
| Mar 31, 2022 | -7.21 Mn |
| Dec 31, 2021 | -6.28 Mn |
| Sep 30, 2021 | -2.67 Mn |